Harbour Biomed Ltd. has obtained FDA clearance of its IND application to initiate a first-in-human...

Vanda Pharmaceuticals Inc. has announced FDA approval of its IND application to evaluate VCA...

The FDA has awarded orphan drug designation to Juvena Therapeutics Inc.’s JUV-161, an...

Increased expression of B7-H3 has been previously reported in multiple solid tumors, including pancreatic cancer. In a recent article, researchers from the University of Tuebingen discussed the development of a novel Fc-optimized monoclonal antibody (MAb) targeting B7-H3, named B7-H3-SDIE, as a new immunotherapeutic treatment option for pancreatic cancer.

Additional early-stage research and drug discovery news in brief, from: IGC Pharma.

Bioversys AG has described 3-(phenylsulfonyl)-[1,2,3]triazolo[1,5a]quinazolin-5(4h)-one derivatives with the ability to interact with accessory gene regulator A (AgrA) and inhibit the expression of AgrA-regulated virulence factors reported to be useful for the treatment of bacterial infections and skin inflammation.